Disclosed herein is novel double-stranded short interfering ribonucleic acid (siRNA) capable of suppressing the translation ofAurora-AmRNA. Also disclosed are use of the novel siRNA as disclosed herein for manufacturing a medicament suitable for treating a cancer, which is mediated through epidermal growth factor receptor (EGFR) signaling. Accordingly, a pharmaceutical composition comprising the disclosed novel siRNA molecules is provided as well as a method of treating a subject suffering from EGFR-mediated cancer via administering to the subject the disclosed novel siRNA molecule.在此揭示新穎的雙股短干擾核糖核酸分子(siRNA),其係可抑制細胞內Aurora-A基因之mRNA的轉譯。本文同時也揭示以這些新穎siRNA來製造癌症藥物的用途,該癌症藥物是可治療經由表皮生長因子受體(EGFR)訊遞機制所媒介之癌症。因此,本文還提供了包含所揭示siRNA分子的藥學組合物,以及透過施用所揭示siRNA分子至亟需治療之個體身上,來治療該個體身上經由EGFR媒介之癌症。
